Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Gale, 1984, How does bone-marrow transplantation cure leukaemia?, Lancet, 2, 28, 10.1016/S0140-6736(84)92009-9 Arai, 2021, Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan, Blood Cell Therapy, 4, 35 Phelan Anasetti, 2012, Peripheral-blood stem cells versus bone marrow from unrelated donors, N Engl J Med, 367, 1487, 10.1056/NEJMoa1203517 Passweg, 2021, Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years, Bone Marrow Transplant, 56, 1651, 10.1038/s41409-021-01227-8 Rowley, 2001, Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation, Blood, 97, 2541, 10.1182/blood.V97.9.2541 Karlsson, 2004, Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue, Bone Marrow Transplant, 33, 709, 10.1038/sj.bmt.1704418 Eapen, 2007, Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival, Biol Blood Marrow Transplant, 13, 1461, 10.1016/j.bbmt.2007.08.006 Eapen, 2015, Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy, Biol Blood Marrow Transplant, 21, 55, 10.1016/j.bbmt.2014.09.006 D'Souza, 2020, Current Use of and Trends in Hematopoietic Cell Transplantation in the United States, Biol Blood Marrow Transplant, 26, e177, 10.1016/j.bbmt.2020.04.013 Zeiser, 2015, Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey, Leukemia, 29, 2062, 10.1038/leu.2015.212 Miklos, 2017, Ibrutinib for chronic graft-versus-host disease after failure of prior therapy, Blood, 130, 2243, 10.1182/blood-2017-07-793786 Nava, 2020, Bone Marrow Transplant, 55, 1126, 10.1038/s41409-020-0818-4 Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2020: The Japanese Data Center for Hematopoietic Cell Transplantation/The Japan Society for Hematopoietic. Cell Transplantation. http://www.jdchct.or.jp/data/report/2020/ Goto, 2018, Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan, Int J Hematol, 107, 211, 10.1007/s12185-017-2341-y Atsuta, 2016, Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data), Int J Hematol, 103, 3, 10.1007/s12185-015-1894-x Kanda, 2016, Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation, Int J Hematol, 103, 11, 10.1007/s12185-015-1907-9 Sullivan, 1991, Chronic graft-versus-host disease and other late complications of bone marrow transplantation, Semin Hematol, 28, 250 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Holtan, 2015, Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, 125, 1333, 10.1182/blood-2014-10-609032 De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660 Yanada, 2018, Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients, Leuk Lymphoma, 59, 601, 10.1080/10428194.2017.1357173 Giralt, 2009, Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 15, 367, 10.1016/j.bbmt.2008.12.497 Morishima, 2002, The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors, Blood, 99, 4200, 10.1182/blood.V99.11.4200 Eapen, 2015, Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation, J Clin Oncol, 33, 364, 10.1200/JCO.2014.57.2446 Worel, 2015, Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues, Biol Blood Marrow Transplant, 21, 2052, 10.1016/j.bbmt.2015.08.009 Nagafuji, 2010, Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry, Int J Hematol, 91, 855, 10.1007/s12185-010-0581-1 Yanada, 2020, Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation, Biol Blood Marrow Transplant, 26, 307, 10.1016/j.bbmt.2019.09.036 Young, 2016, Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors, Biol Blood Marrow Transplant, 22, 359, 10.1016/j.bbmt.2015.09.013 Laskin, 2011, Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy, Blood, 118, 1452, 10.1182/blood-2011-02-321315 Poutsiaka, 2011, Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated, Bone Marrow Transplant, 46, 300, 10.1038/bmt.2010.112 Dalle, 2016, Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment, Biol Blood Marrow Transplant, 22, 400, 10.1016/j.bbmt.2015.09.024 Noguchi, 2020, Hemophagocytic Lymphohistiocytosis and Graft Failure Following Unrelated Umbilical Cord Blood Transplantation in Children, J Pediatr Hematol Oncol, 42, e440, 10.1097/MPH.0000000000001795 Savani, 2016, Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT, Haematologica, 101, 256, 10.3324/haematol.2015.135699 Kanda, 2016, Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations, Biol Blood Marrow Transplant, 22, 744, 10.1016/j.bbmt.2015.12.027 Lee, 2016, Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial, JAMA Oncol, 2, 1583, 10.1001/jamaoncol.2016.2520 Byrne, 2016, Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Exp Hematol, 44, 567, 10.1016/j.exphem.2016.04.005 Kolb, 2008, Graft-versus-leukemia effects of transplantation and donor lymphocytes, Blood, 112, 4371, 10.1182/blood-2008-03-077974 Nakamura, 2021, Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation, Br J Haematol, 194, 403, 10.1111/bjh.17646 Yeshurun, 2019, The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia, Blood Adv, 3, 670, 10.1182/bloodadvances.2018027003 Bacigalupo, 2001, Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, 98, 2942, 10.1182/blood.V98.10.2942 Bacigalupo, 2006, Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation, Biol Blood Marrow Transplant, 12, 560, 10.1016/j.bbmt.2005.12.034 Finke, 2009, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, 10, 855, 10.1016/S1470-2045(09)70225-6 Wang, 2014, Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial, Bone Marrow Transplant, 49, 426, 10.1038/bmt.2013.191 Kroger, 2016, Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease, N Engl J Med, 374, 43, 10.1056/NEJMoa1506002 Walker, 2020, Lancet Haematol, 7, e100, 10.1016/S2352-3026(19)30220-0 Ofran, 2019, Br J Haematol, 184, 643, 10.1111/bjh.15131 Socie, 2011, Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius, Blood, 117, 6375, 10.1182/blood-2011-01-329821 Nagler, 2019, Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI, Blood Adv, 3, 1950, 10.1182/bloodadvances.2019000030 Soiffer, 2017, Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation, J Clin Oncol, 35, 4003, 10.1200/JCO.2017.75.8177 Shiratori, 2021, Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors, Bone Marrow Transplant, 56, 2231, 10.1038/s41409-021-01314-w Nagler, 2012, Biol Blood Marrow Transplant, 18, 1422, 10.1016/j.bbmt.2012.02.013 Fuji, 2019, Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT, Int J Hematol, 109, 684, 10.1007/s12185-019-02631-z Sasazuki, 1998, Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program, N Engl J Med, 339, 1177, 10.1056/NEJM199810223391701 Jagasia, 2015, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 21, 389, 10.1016/j.bbmt.2014.12.001